Attorneys in the Corporate & Securities and Life Sciences Practices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., together with European counsel, recently represented QIAGEN N.V. in a major offering of convertible notes. The transactions included the simultaneous repurchase from non-U.S. holders of approximately $291 million of outstanding convertible notes, the issuance of $730 million aggregate principal amount of new senior unsecured cash-settled convertible notes outside the United States, and the implementation of a call spread overlay increasing the effective strike price of the new convertible notes from QIAGEN’s perspective.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research).
Representing QIAGEN in the offering were Jonathan L. Kravetz, Chair of the firm’s Securities Practice Group and one of the core members of the Life Sciences Practice Group, Daniel H. Follansbee, a Member of the Corporate & Securities Practice, Leonard Weiser-Varon, a Member of the Public Finance Practice, Paul J. Ricotta, a Member of the Bankruptcy, Restructuring & Commercial Law Practice, Megan N. Gates, Co-Chair of the Securities Practice, and J.R. Urbon, an associate in the Corporate & Securities Practice.
Mintz Levin has served as one of the leading law firms to the life sciences industry since the industry’s birth in the 1970s. Today, we advise hundreds of businesses and other organizations in all sectors of the industry’s ecosystem -- from start-ups looking for their first funding to public companies with products on the market, as well as venture capital firms, investment banks, and research and academic institutions. Our attorneys provide experienced counsel to clients globally in a broad range of matters, including corporate finance and securities, mergers and acquisitions, licensing and collaborations, intellectual property, litigation, regulatory, antitrust, employment and benefits, bankruptcy and commercial lending, immigration, and real estate. Mintz Levin is a full-service law firm comprised of 470 attorneys with eight offices (Boston, New York, San Diego, San Francisco, Washington, Stamford, Los Angeles, and London) and an affiliate relationship in Israel.